Prana Enrolls First Patient in the "Reach2HD" Phase II Huntington Disease Trial
Prana Biotechnology (NASDAQ: PRAN) today announced that the first patient has been dosed in the "Reach2HD Trial" - a 6 month Phase IIa clinical trial testing PBT2, the Company's drug in development for Huntington disease. Reach2HD, a double blind placebo controlled study, is enrolling 100 patients with early to mid-stage Huntington Disease. The Principal Investigator on the study is Dr. Ray Dorsey of Johns Hopkins University.
Huntington disease is a complex and severely debilitating genetic, neurodegenerative disease, for which there is no cure. The disease often affects young adults and, whilst associated with severe physical movement symptoms, progressively impacts the mind and emotions as well. The disease causes incapacitation and death about 15-25 years after onset. The disease affects 30,000 people in the US and about 70,000 worldwide.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.